Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during mid-day trading, an increase of 273% from the average daily volume of 1,816 shares. The stock had previously closed at $18.73.
PureTech Health Stock Down 6.3 %
The firm’s 50-day moving average is $20.91 and its two-hundred day moving average is $21.35.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
- Five stocks we like better than PureTech Health
- The 3 Best Blue-Chip Stocks to Buy Now
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Insider Buying Explained: What Investors Need to Know
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
